Physician profile
Justin Wasserman
NPI 1952400798
$50,525.34
in general payments reported to CMS, 2019-2025
23 companies · $431 in 2025
The $431 reported for 2025 was more than what 76% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $301 · 2020: $67.69 · 2021: $1,399 · 2022: $11K · 2023: $23K · 2024: $14K · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Travel and Lodging: $4,077 · Food and Beverage: $1,909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,387.50 |
| Travel and Lodging | $4,076.78 |
| Food and Beverage | $1,908.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $47,185.29 | 2022-2024 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $1,212.17 | 2021 | |
| Abbvie INC. | $968.35 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Orexo US, INC. | $233.72 | 2019-2025 | Zubsolv |
| Collegium Pharmaceutical, INC. | $173.82 | 2020-2025 | Belbuca, Nucynta |
| Pfizer INC. | $123.74 | 2019-2025 | |
| Vertex Pharmaceuticals Incorporated | $95.46 | 2025 | |
| Lilly USA, LLC | $91.54 | 2020-2023 | Emgality, Reyvow |
| Biohaven Pharmaceutical Holding Company LTD. | $60.60 | 2022 | |
| Novartis Pharmaceuticals Corporation | $55.72 | 2019 | |
| Arbor Pharmaceuticals, INC. | $45.90 | 2019 | |
| Biodelivery Sciences International, INC. | $44.29 | 2019-2020 | |
| Amgen INC. | $39.74 | 2019 | |
| Merck Sharp & Dohme LLC | $31.79 | 2022-2023 | Belsomra |
| Axsome Therapeutics, INC. | $30.41 | 2025 | Symbravo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $29.04 | 2021 | |
| Scilex Pharmaceuticals INC. | $18.04 | 2023 | Ztlido |
| Antares Pharma, INC. | $16.24 | 2019 | |
| Acadia Pharmaceuticals INC | $15.83 | 2019 | |
| Novo Nordisk INC | $14.31 | 2023 | Saxenda, Wegovy |
| Tonix Medicines, INC. | $14.15 | 2025 | Tonmya |
| Zimmer Biomet Holdings, INC. | $13.66 | 2020 | |
| Allergan, INC. | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Wasserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.